Cargando…

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib

The effect of folate status on breast cancer resistance protein (BCRP)-mediated drug resistance to epidermal growth factor receptor (EGFR)-targeted drugs, such as gefitinib and erlotinib, was investigated in two human colon cancer cell lines, WiDr and Caco-2, of which the latter displayed greater se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemos, C, Kathmann, I, Giovannetti, E, Calhau, C, Jansen, G, Peters, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669988/ https://www.ncbi.nlm.nih.gov/pubmed/19277036 http://dx.doi.org/10.1038/sj.bjc.6604980

Ejemplares similares

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients
por: Hussien, M M I, et al.
Publicado: (2005)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging
por: Qawasmi, Israa, et al.
Publicado: (2014)

Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa
por: Piazzi, G, et al.
Publicado: (2006)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
por: Lemos-González, Y, et al.
Publicado: (2007)

A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT
por: Bryant, J L, et al.
Publicado: (2012)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status
por: Hofman, P, et al.
Publicado: (2008)

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
por: Maftouh, M, et al.
Publicado: (2014)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
por: Maseki, S, et al.
Publicado: (2012)

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
por: Krubasik, D, et al.
Publicado: (2006)

Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases
por: Goos, J A C M, et al.
Publicado: (2014)

Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor
por: Kim, Hyeryeong, et al.
Publicado: (2017)

Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
por: Prang, N, et al.
Publicado: (2005)

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2006)

Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer
por: Michikawa, C, et al.
Publicado: (2011)

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
por: Savic, S, et al.
Publicado: (2008)

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma
por: Sonobe, M, et al.
Publicado: (2005)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015)

The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer
por: Richards, C H, et al.
Publicado: (2012)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
por: Gray-Schopfer, V C, et al.
Publicado: (2006)

Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma
por: Lau, Y S, et al.
Publicado: (2007)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients
por: Hawinkels, L J A C, et al.
Publicado: (2007)

Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia
por: Nankivell, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fh8t5bh2meaes8et6vhv0h7j8j